• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38283.85
  • 0.68 %
  • 257.6797
  • FTSE
  • 8262.08
  • 1.38 %
  • 112.8101
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
Novo Nordisk A/S (NVO) Stock Price, News & Analysis

Novo Nordisk A/S (NVO) Stock Price, News & Analysis

Currency in USD Disclaimer

$105.08

$2.45

(2.39%)

Day's range
$103.86
Day's range
$106.23
50-day range
$99.42
Day's range
$138.22
  • Country: DK
  • ISIN: US6701002056
52 wk range
$94.73
Day's range
$148.15
  • CEO: Mr. Lars Fruergaard Jorgensen
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 3.13
  • Piotroski Score 7.00
  • Grade Overweight
  • Symbol (NVO)
  • Company Novo Nordisk A/S
  • Price $105.08
  • Changes Percentage (2.39%)
  • Change $2.45
  • Day Low $103.86
  • Day High $106.23
  • Year High $148.15

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

  • Last Earnings 08/06/2024
  • Ex-Dividend for 5/16 Dividend 08/16/2024
  • Dividend Payable 08/26/2024
  • Today N/A
  • Next Earnings (Estimated) 01/29/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $158.00
  • High Stock Price Target $160.00
  • Low Stock Price Target $156.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $2.90
  • Trailing P/E Ratio 49.27
  • Forward P/E Ratio 49.27
  • P/E Growth 49.27
  • Net Income $83.68 B

Income Statement

Quarterly

Annual

Latest News of NVO

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Novo Nordisk A/S Frequently Asked Questions

  • What is the Novo Nordisk A/S stock price today?

    Today's price of Novo Nordisk A/S is $105.08 — it has increased by +2.39% in the past 24 hours. Watch Novo Nordisk A/S stock price performance more closely on the chart.

  • Does Novo Nordisk A/S release reports?

    Yes, you can track Novo Nordisk A/S's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Novo Nordisk A/S stock forecast?

    Watch the Novo Nordisk A/S chart and read a more detailed Novo Nordisk A/S stock forecast to see what analysts suggest you do with its shares.

  • What is Novo Nordisk A/S stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NYSE, exchange stock trades by Novo Nordisk A/S stock ticker.

  • How to buy Novo Nordisk A/S stocks?

    Like other stocks, NVO shares are sold on stock exchanges such as NYSE. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Novo Nordisk A/S's EBITDA?

    Novo Nordisk A/S measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Novo Nordisk A/S’s financial statements.

  • What is the Novo Nordisk A/S's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0.3602972518, which equates to approximately 36.03%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Novo Nordisk A/S stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Novo Nordisk A/S's financials relevant news, and technical analysis. Novo Nordisk A/S's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Novo Nordisk A/S stock currently indicates a “sell” signal. For more insights, review Novo Nordisk A/S’s technical analysis.

  • A revenue figure for Novo Nordisk A/S for its last quarter?

    Novo Nordisk A/S published it's last quarterly revenues at $71.31 B.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.